4//SEC Filing
KYTHERA BIOPHARMACEUTICALS INC 4
Accession 0001104659-15-068865
CIK 0001436304operating
Filed
Oct 1, 8:00 PM ET
Accepted
Oct 2, 2:18 PM ET
Size
28.2 KB
Accession
0001104659-15-068865
Insider Transaction Report
Form 4
Leonard Keith R
DirectorPresident and CEO
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2015-10-01−81,306→ 0 totalExercise: $5.90Exp: 2020-10-14→ Common Stock (81,306 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−89,542→ 0 totalExercise: $44.02Exp: 2024-01-02→ Common Stock (89,542 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−151,302→ 0 totalExercise: $38.53Exp: 2025-01-29→ Common Stock (151,302 underlying) - Gift
Common Stock
2015-07-21−66,667→ 763,076 total(indirect: See Footnote) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−50,400→ 0 totalExercise: $27.50Exp: 2023-01-29→ Common Stock (50,400 underlying) - Gift
Common Stock
2015-08-18−400,000→ 363,076 total(indirect: See Footnote) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−33,600→ 0 totalExercise: $27.50Exp: 2023-01-29→ Common Stock (33,600 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−51,223→ 0 totalExercise: $8.22Exp: 2022-02-01→ Common Stock (51,223 underlying) - Disposition to Issuer
Common Stock
2015-10-01−363,076→ 0 total(indirect: See Footnote) - Disposition to Issuer
Common Stock
2015-10-01−9,105→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−28,082→ 0 totalExercise: $5.50Exp: 2020-01-15→ Common Stock (28,082 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−34,148→ 0 totalExercise: $8.22Exp: 2022-02-01→ Common Stock (34,148 underlying)
Footnotes (4)
- [F1]Disposed of pursuant to the Amended and Restated Agreement and Plan of Merger dated as of August 4, 2015 (the "Merger Agreement" and the transactions contemplated therein, the "Merger"), by and among Allergan plc (formerly known as Actavis plc) ("Allergan"), Keto Merger Sub, Inc. (a wholly owned subsidiary of Allergan) and Issuer, whereby each share of Issuer common stock was canceled in exchange for $75.00 in cash, without interest.
- [F2]The Reporting Person no longer has reportable beneficial interests in 189 shares of Issuer common stock held by Keith R. Leonard III, the Reporting Person's son, or 189 shares of Issuer common stock held by Nina R. Leonard, the Reporting Person's daughter. On April 12, 2015, an independent third-party was appointed trustee of each of Keith Richard Leonard, Jr., Retained Annuity Trust, Dated 12 April, 2010, Keith Richard Leonard, Jr., Trustee (the "KL GRAT") and Nanette LaRosa Leonard, Retained Annuity Trust, Dated 12 April, 2010, Keith Richard Leonard, Jr., Trustee (the "NL GRAT") and the Reporting Person ceased to serve as trustee thereof. Accordingly, the Reporting Person no longer has a reportable beneficial interest in 47,103 shares of Issuer common stock previously held by the KL GRAT or 47,103 shares of Issuer common stock previously held by the NL GRAT.
- [F3]Shares held by Leonard Family Trust, dated August 28, 1996, Keith Richard Leonard, Jr. and Nannette LaRosa Leonard, Trustees.
- [F4]Pursuant to the Merger Agreement, each option to purchase common stock was canceled and paid in cash assuming a stock price of $75.00.
Documents
Issuer
KYTHERA BIOPHARMACEUTICALS INC
CIK 0001436304
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001436304
Filing Metadata
- Form type
- 4
- Filed
- Oct 1, 8:00 PM ET
- Accepted
- Oct 2, 2:18 PM ET
- Size
- 28.2 KB